Unknown

Dataset Information

0

Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.


ABSTRACT: The four dengue virus serotypes (DENV1-4) are responsible for the most prevalent mosquito-borne viral illness in humans. DENV causes a spectrum of disease from self-limiting dengue fever (DF) to severe, life-threatening dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Antibodies from one infection can contribute to either protection or increased disease severity in a subsequent infection with a distinct DENV serotype. The effectiveness of the antibody response is modulated by both the affinity and avidity of the antibody/antigen interaction.We investigated how antibody avidity developed over time following secondary DENV2 infection across different disease severities.We analyzed sera from 42 secondary DENV2-infected subjects (DF, n=15; DHF, n=16; DSS, n=11) from a pediatric hospital-based dengue study in Nicaragua. IgG avidity against DENV2 virions was measured in samples collected during acute and convalescent phases as well as 3, 6, and 18 months post-illness using a urea enzyme-linked immunosorbent assay.The data show a significant increase in avidity from acute to convalescent phase followed by a decrease from convalescent phase to 3 months post-symptom onset, then a plateau. Linear regression analysis comparing antibody avidity between disease severity groups over time indicate that individuals with more severe disease (DHF/DSS) experienced greater decay in antibody avidity over time compared to less severe disease (DF), and ROC curve analysis showed that at 18 months post-illness, lower avidity was associated with previously having experienced more severe disease.These data suggest that increased dengue disease severity is associated with lower antibody avidity at later time-points post-illness.

SUBMITTER: Lau L 

PROVIDER: S-EPMC4978614 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.

Lau Louis L   Green Angela M AM   Balmaseda Angel A   Harris Eva E  

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20150605


<h4>Background</h4>The four dengue virus serotypes (DENV1-4) are responsible for the most prevalent mosquito-borne viral illness in humans. DENV causes a spectrum of disease from self-limiting dengue fever (DF) to severe, life-threatening dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Antibodies from one infection can contribute to either protection or increased disease severity in a subsequent infection with a distinct DENV serotype. The effectiveness of the antibody response is modu  ...[more]

Similar Datasets

| S-EPMC8262508 | biostudies-literature
| S-EPMC3910643 | biostudies-literature
2017-03-08 | E-MTAB-4692 | biostudies-arrayexpress
| S-EPMC4877104 | biostudies-literature
| S-EPMC6675051 | biostudies-literature
| S-EPMC5234037 | biostudies-literature
| S-EPMC5430213 | biostudies-literature
| S-EPMC9321390 | biostudies-literature
| S-EPMC3681624 | biostudies-literature
| S-EPMC6047418 | biostudies-literature